INOVIQ LTD — Director's Dealing 2020

Dec 7, 2020

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity BARD1 Life Sciences Limited

ABN 58 009 070 384

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

We (the entity) give ASX the followingthe director for the purposes of section	information under listing rule 3.19A.2 and as agent for205G of the Corporations Act.
Name of Director	Dr Geoffrey Cumming
Date of last notice	24 August 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest	Jamelys Superannuation Fund
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change	4 December 2020
No. of securities held prior to change	- 88,347 ordinary fully paid shares –
	Jamelys Superannuation Fund (following
	the 1 for 30 share consolidation)
	- 27,413 ordinary fully paid shares – Dr
	Geoffrey Cumming (following the 1 for 30
	share consolidation)
	- 52,000 unlisted BD1 incentive options –
	Dr Geoffrey Cumming (following the 1 for
	30 share consolidation)
Class	Ordinary Fully Paid Shares
Number acquired	9,333
Number disposed	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

	Value/ConsiderationNote: If consideration is non-cash, provide details and estimated	Value/ConsiderationNote: If consideration is non-cash, provide details and estimated	An average of $0.7571 per ordinary share	An average of $0.7571 per ordinary share	An average of $0.7571 per ordinary share
	valuation
	No. of securities held af	ter change	- 97,680 ordinary fully	paid shares –
			Jamelys Superannuation- 21 ordinar full	Fundaid shares – Dr
			7,43 y yGeoffrey Cumming
			- 52,000 unlisted BD1 inc	entive options –
			Dr Geoffrey Cumming
	Nature of change		On-market purchase
	Example: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participation inbuy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Were the interests in the securitabove traded during a+closed peclearance was required?If so, was prior written clearanctrade to proceed during this perioIf prior written clearance was prothis provided?	Were the interests in the securitabove traded during a+closed peclearance was required?If so, was prior written clearanctrade to proceed during this perioIf prior written clearance was prothis provided?
	Were the interests in the securitabove traded during a+closed peclearance was required?	ies or contriod where	racts detailedprior written	No
	If so, was prior written clearanctrade to proceed during this perio	e providedd?	to allow the	N/A
	If prior written clearance was prothis provided?	vided, on w	hat date was	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3